Among all the hospital germs, Gram-negative bacteria are particularly difficult to treat: Many antibiotics fail due to the double-cell membrane. But cystobactamides are providing hope for a remedy – substances from the...
The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute for Pharmaceutical Research...
Am Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) findet am 27. und 28. Juni zum neunten Mal das HIPS-Symposium statt. In diesem Rahmen wird gleichzeitig das 10-jährige Jubiläum des Saarbrücker...
Medically relevant compounds can often be found in nature. To make them suitable for drugs, they need to be isolated from their natural sources. If sufficient quantities of the agent cannot be isolated in that manner,...
An increasing number of bacteria are developing resistance to commonly used antibiotics, making it imperative to advance research into new antibiotics for clinical and medical use. Olga Kalinina, the new endowed...
The treatment of hepatitis C has been based on specific effective antiviral medications for a number of years. Since future development of resistance cannot be ruled out, alternative treatment options are being...
Dendritic cells act as the guardians of our immune system. They are lurking for foreign invaders, swallow them, break them into pieces and present the fragments on the cell surface. When the dendritic cells and their...
On 20 February 2019, the Helmholtz Centre for Infection Research (HZI) and Evotec AG announced their cooperation, scheduled for three years initially. They aim to develop new antibiotics that overcome resistant...
